早期临床反应终点：美国食品药品监督管理局选对时机了吗？ - Suppr

Suppr

超能文献

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

作者信息

Talbot George H

机构信息

Talbot Advisors LLC, Anna Maria, Florida

出版信息

Clin Infect Dis. 2017 Jan 15;64(2):218-220. doi: 10.1093/cid/ciw752. Epub 2016 Dec 21.

DOI:10.1093/cid/ciw752

PMID:28003217

Abstract

摘要

相似文献

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

Clin Infect Dis. 2017 Jan 15;64(2):218-220. doi: 10.1093/cid/ciw752. Epub 2016 Dec 21.

Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.

Clin Infect Dis. 2021 Nov 2;73(9):e2613-e2615. doi: 10.1093/cid/ciaa853.

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Clin Infect Dis. 2012 Oct;55(8):1114-21. doi: 10.1093/cid/cis566. Epub 2012 Jun 28.

New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S469-76. doi: 10.1093/cid/cir162.

FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S4-9. doi: 10.1093/cid/cit612.

Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.

Expert Rev Clin Pharmacol. 2015 Jan;8(1):141-53. doi: 10.1586/17512433.2015.986461. Epub 2014 Dec 3.

Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).

J Chemother. 2016 Jun;28(3):180-6. doi: 10.1179/1973947815Y.0000000010.

Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.

Antimicrob Agents Chemother. 2015 Aug;59(8):4510-20. doi: 10.1128/AAC.00679-15. Epub 2015 May 18.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Ann Pharmacother. 2011 Nov;45(11):1384-98. doi: 10.1345/aph.1Q225. Epub 2011 Oct 18.

Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).

Curr Med Res Opin. 2013 Jul;29(7):869-77. doi: 10.1185/03007995.2013.803056. Epub 2013 May 23.

引用本文的文献

Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.

Clin Infect Dis. 2021 Nov 2;73(9):e2613-e2615. doi: 10.1093/cid/ciaa853.

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Open Forum Infect Dis. 2020 Apr 24;7(5):ofaa145. doi: 10.1093/ofid/ofaa145. eCollection 2020 May.

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.02252-18. Print 2019 Jul.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

作者信息

Talbot George H

机构信息

Talbot Advisors LLC, Anna Maria, Florida

出版信息

Clin Infect Dis. 2017 Jan 15;64(2):218-220. doi: 10.1093/cid/ciw752. Epub 2016 Dec 21.

DOI:10.1093/cid/ciw752

PMID:28003217

Abstract

摘要